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Summary
In order to investigate the role of mitochondrial acyl-CoA:glycerol-sn-3-phosphate acyltransferase 1 (mtGPAT1) in the
pathogenesis of hepatic steatosis and hepatic insulin resistance, we examined whole-body insulin action in awake
mtGPAT1 knockout (mtGPAT1−/−) and wild-type (wt) mice after regular control diet or three weeks of high-fat feeding. In
contrast to high-fat-fed wt mice, mtGPAT1−/− mice displayed markedly lower hepatic triacylglycerol and diacylglycerol
concentrations and were protected from hepatic insulin resistance possibly due to a lower diacylglycerol-mediated PKC
activation. Hepatic acyl-CoA has previously been implicated in the pathogenesis of insulin resistance. Surprisingly, com-
pared to wt mice, mtGPAT1−/− mice exhibited increased hepatic insulin sensitivity despite an almost 2-fold elevation in
hepatic acyl-CoA content. These data suggest that mtGPAT1 might serve as a novel target for treatment of hepatic
steatosis and hepatic insulin resistance and that long chain acyl-CoA’s do not mediate fat-induced hepatic insulin resis-
tance in this model.Introduction
Concurrent with the existing epidemic of obesity, hepatic
steatosis is rapidly becoming a major health care problem.
Hepatic steatosis is associated with altered liver function, hy-
perlipidemia, and progression to liver cirrhosis (Lee, 1989;
Marchesini et al., 1999). Furthermore recent studies have dem-
onstrated an important role of hepatic steatosis in the patho-
genesis of hepatic insulin resistance, increased hepatic gluco-
neogenesis, and fasting hyperglycemia in patients with type 2
diabetes (Mayerson et al., 2002, Petersen et al., 2005; Petersen
et al., 2002; Pietilainen et al., 2005). Understanding the steps
involved in the regulation of hepatic triacylglycerol synthesis
might be expected to yield important new information regard-
ing the pathogenesis of nonalcoholic fatty liver disease
(NALFD) and hepatic insulin resistance as well as providing po-
tential novel targets for their treatment and prevention.
In this context, we examined whether or not a mouse model
deficient in the mitochondrial isoform of acyl-CoA:glycerol-sn-
3-phosphate acyltransferase 1 (mtGPAT1) would be protected
from fat-induced hepatic steatosis and hepatic insulin resis-
tance. GPAT has been hypothesized to control the rate-con-
trolling step in the glycerol 3-phosphate pathway, catalyzing
the acylation of glycerol-3-phosphate with acyl-coenzyme A
(CoA) generating CoA and 1-acyl-sn-glycerol 3-phosphate (ly-
sophosphatidic acid, Figure 1). Three different isoenzymes of
GPAT have been described to date, one located in the endo-
plasmic reticulum (msGPAT) and two in the outer mitochondrial
membrane (mtGPAT1 and mtGPAT2; Bhat et al., 1999; Cole-CELL METABOLISM : JULY 2005 · VOL. 2 · COPYRIGHT © 2005 ELSEVIman and Haynes, 1983; Coleman and Lee, 2004; Lewin et al.,
2004; Monroy et al., 1972; Shin et al., 1991). Among these
three isoforms only mtGPAT1 has been sequenced (Bhat et
al., 1999; Paulauskis and Sul, 1988; Shin et al., 1991; Yet et
al., 1993).
Previous in vitro studies have demonstrated that overexpres-
sion of mtGPAT in cell cultures primarily results in the traffick-
ing of exogenous fatty acids into the triacylglycerol pool rather
than incorporation into phospholipid fractions or into oxidative
degradation (Igal et al., 2001; Lindén et al., 2004). Thus, it has
been proposed that the mitochondrial mtGPAT1 isoform might
serve as a valve that channels fatty-acid derivatives preferen-
tially toward glycerolipid synthesis, counteracting their parti-
tioning into the β-oxidation pathway (Lewin et al., 2005; Ham-
mond et al., 2002).
The glycerol-3-phosphate pathway provides lipid metabo-
lites, such as acyl-CoA, lysophosphatidic acid, diacylglycerol,
and triacylglycerol (Figure 1), which have all been suggested to
play a role in the development of insulin resistance (Griffin et
al., 1999; Jucker et al., 1999; Kraegen et al., 2001; Neschen et
al., 2002; Samuel et al., 2004; Shulman, 2000; Yu et al., 2002).
Since liver is among the organs displaying the highest specific
mtGPAT enzyme activity, we surmised that systemic mtGPAT1
deletion in mice would affect acyl-CoA, lysophosphatidic acid,
diacylglycerol, and triacylglycerol abundance predominantly in
the liver and that these alterations in lipid metabolites might
provide some novel insights into the pathogenesis of hepatic
steatosis and hepatic insulin resistance.ER INC. DOI 10.1016/j.cmet.2005.06.006 55
A R T I C L EFigure 1. Glycerol-3-phosphate pathway
The glycerol 3-phosphate or phosphatidic acid
pathway represents the de novo route in the synthe-
sis of triacylglycerol (TAG) and phospholipids. acyl-
CoA:glycerol-sn-3-phosphate acyltransferase (GPAT)
catalyzes the acylation of sn-glycerol-3-phosphate
with acyl-coenzyme A (acyl-CoA) generating lyso-
phosphatidic acid (LPA), which is thought to be the
rate-controlling step in triglyceride synthesis. Sub-
sequent reactions are catalyzed by acyl-CoA:1-
acylglycerol-sn-3-phosphate acyltransferase (AGPAT),
phosphatidic acid phosphatase (PAP), and diacylglyc-
erol:acyl-CoA acyltransferase (DGAT) isoenzymes
generating phosphatidic acid (PA), diacylglycerol
(DAG), and triacylglycerol (TAG). In liver, triacylglyc-
erol is either deposited in intracellular lipid vacuoles
or exported in very low-density lipoprotein (VLDL)
particles. Lysophosphatidic and phosphatidic acid
generated at cell organelles other than the endo-
plasmic reticulum require translocation through the
cytosol for triacylglycerol synthesis at the endoplas-
mic reticulum (modified from Coleman and Lee,
2004).Results
Metabolic phenotype and glucose tolerance in regular
chow- and high-fat-diet-fed mtGPAT1−/− and wt mice
To evaluate the effect of mtGPAT1 deletion on whole-body
physiology, we assessed food intake, fat absorption, body
weight, whole body fat content, as well as plasma metabolite
and hormone concentrations from mtGPAT1−/− and wt mice
fed a control diet or a high-fat diet for three weeks (Table 1).
Body weights and plasma concentrations of glucose, fatty
acids, insulin, glucagon, adiponectin, and leptin did not differ
among mtGPAT1−/− and wt mice fed the control diet. In con-
trast, plasma triacylglycerol concentrations and whole-body fat
mass were w30% and w20% lower in mtGPAT1−/− mice com-
pared to the wt mice (Table 1).
When the control diet was changed to a high-fat diet,
mtGPAT1−/− mice consumed a higher amount of dietary calo-
ries but also absorbed less fat from the diet than wt mice, re-
sulting in an overall similar weight gain. Plasma concentrations
of glucose, fatty acids, insulin, glucagon, corticosterone, resis-
tin, adiponectin, and leptin did not differ among mtGPAT1−/− and
wt mice after 3 weeks of high-fat feeding, but plasma triglycer-
ides were 30% lower in the mtGPAT1−/− mice (Table 1).
When fed a control diet, mtGPAT1−/− and wt mice displayed
similar plasma-glucose and insulin responses following an in-
traperitoneal glucose challenge (Figures 2A and 2C). Following
only one week of high-fat feeding, mtGPAT1−/− mice displayed
a markedly improved glucose tolerance compared to wt mice
(Figures 2B and 2D).
Hyperinsulinemia (197 ± 22, n = 7 versus 176 ± 25, n = 7
U/ml insulin in wt) in response to an intraperitoneal insulin
injection decreased plasma fatty acid (0.42 ± 0.03, n = 7 versus560.48 ± 0.04, n = 7 mmol/l nonesterified fatty acids in wt) and
triacylglycerol (53 ± 4, n = 7 versus 67 ± 6, n = 7 mmol/l triacyl-
glycerol in wt) concentrations to a comparable extent in high-
fat-diet-fed mtGPAT1−/− and wt mice. Under hyperinsulinemic
conditions, plasma resistin (4.9 ± 0.7, n = 4 versus 4.8 ± 0.7,
n = 3 ng/ml in wt) and β-hydroxybutyrate levels did not differ
between genotypes (0.36 ± 0.14, n = 5 versus 0.43 ± 0.06, n =
4 β-hydroxybutyrate in wt). Relative to the fasting state,
β-hydroxybutyrate concentrations declined more than 4-fold
with insulin stimulation in mtGPAT1−/− compared to only 2-fold
in high-fat-diet-fed wt mice (Table 1).
Improved insulin sensitivity in high-fat-diet-fed
mtGPAT1−/− mice is due to preservation
of hepatic insulin sensitivity
Euglycemic-hyperinsulinemic clamp experiments confirmed no
genotypic differences in whole-body- and organ-specific insu-
lin sensitivity reflected by comparable glucose infusion rates
(Figure 3A), peripheral insulin sensitivity (Figure 3C), and he-
patic insulin sensitivity (Figure 3E).
In contrast, when euglycemic-hyperinsulinemic clamp studies
were performed after three weeks of high-fat diet feeding,
mtGPAT1−/− mice showed increased insulin sensitivity com-
pared to wt mice as reflected by a 40% higher glucose infusion
rate required to maintain euglycemia than in wt mice (Figure
3B). Improved insulin sensitivity in high-fat-diet-fed mtGPAT1−/−
compared to wt mice could almost entirely be attributed to in-
creased hepatic insulin sensitivity. The decline in hepatic insu-
lin sensitivity observed in wt mice fed the high-fat diet was
completely rescued by mtGPAT1 deletion, and insulin sup-
pressed hepatic glucose production by almost 80% in high-
fat-fed versus 82% in control-diet-fed mtGPAT1−/− mice (Fig-CELL METABOLISM : JULY 2005
Mitochondrial GPAT and insulin resistanceTable 1. Physiologic and plasma parameters in wt and mtGPAT1−/− mice
Control diet High-fat diet
wt mtGPAT1−/− wt mtGPAT1−/−
Physiologic parameters
Body weight (g) 27.3 ± 0.3 (n = 25) 27.0 ± 0.4 (n = 22) 29.3 ± 0.5 (n = 25) 28.4 ± 0.5 (n = 22)
Whole-body fat content (%BW) 8.0 ± 0.5 (n = 25) 6.5 ± 0.6* (n = 22) 14.8 ± 0.9 (n = 25) 12.8 ± 0.7 (n = 22)
Whole-body fat gain (%BW/3 weeks) — — 6.8 ± 0.9 (n = 25) 6.3 ± 0.7 (n = 22)
Calorie consumption (kcal/day/g BW) 0.52 ± 0.02 (n = 3) 0.47 ± 0.01 (n = 3) 0.48 ± 0.01 (n = 20) 0.51 ± 0.01* (n = 18)
Fat absorption (% linoleic acid) 99.4 ± 0.2 (n = 5) 98.1 ± 1.0 (n = 5) 99.4 ± 0.2 (n = 5) 97.5 ± 0.4* (n = 5)
Plasma metabolites
Glucose (mg/dl) 147 ± 6 (n = 11) 148 ± 5 (n = 11) 142 ± 7 (n = 13) 143 ± 6 (n = 11)
Total cholesterol (mg/dl) 82 ± 7 (n = 5) 75 ± 3 (n = 5) 103 ± 8 (n = 13) 88 ± 5 (n = 11)
HDL cholesterol (mg/dl) 67 ± 4 (n = 5) 61 ± 2 (n = 5) 78 ± 5 (n = 13) 67 ± 4 (n = 11)
Triacylglycerol (mmol/l) 89 ± 5 (n = 5) 64 ± 3* (n = 5) 121 ± 12 (n = 9) 88 ± 8* (n = 10)
Nonesterified fatty acid (meq/l) 0.74 ± 0.07 (n = 5) 0.70 ± 0.04 (n = 5) 0.83 ± 0.10 (n = 13) 0.73 ± 0.08 (n = 11)
β-hydroxybutyrate (mmol/l) 1.1 ± 0.2 (n = 5) 1.2 ± 0.1 (n = 5) 0.94 ± 0.09 (n = 9) 1.55 ± 0.36* (n = 7)
Plasma hormones and adipocyte cytokines
Insulin (U/ml) 15 ± 1 (n = 6) 16 ± 1 (n = 6) 19 ± 1 (n = 13) 17 ± 2 (n = 11)
Glucagon (pg/ml) n.d. n.d. 64 ± 4 (n = 7) 62 ± 5 (n = 5)
Corticosterone (ng/ml) n.d. n.d. 61 ± 14 (n = 13) 65 ± 9 (n = 11)
Resistin (ng/ml) n.d. n.d. 3.8 ± 0.2 (n = 9) 3.8 ± 0.3 (n = 10)
Adiponectin (g/ml) 19 ± 7 (n = 2) 15 ± 1 (n = 2) 15 ± 1 (n = 13) 15 ± 1 (n = 11)
Leptin (ng/ml) 6.9 ± 0.1 (n = 2) 6.9 ± 1.4 (n = 2) 7.2 ± 1.1 (n = 11) 5.5 ± 0.4 (n = 9)
Physiologic and plasma parameters were determined throughout control diet or at the end of 3 weeks of high-fat diet feeding (*p < 0.05; **p < 0.001; n.d., not
determined).2-associated phosphatidyl inositol-3-kinase activity (PI3K, Fig- mice compared to the wt mice (Figure 4C).
Figure 2. Intraperitoneal glucose tolerance tests
Experiments were performed in wt and mtGPAT1−/−
mice fed either a control diet or high-fat diet for 1
week. For (A and B) plasma-glucose and (C and D)
insulin measurements, a basal blood sample was
obtained at minute 0 from fasting (control diet 16 hr,
high-fat diet 7 hr) mice and additional blood sam-
ples after injection of 1 g glucose/kg BW at minutes
15, 30, 60, and 120. Results are expressed as
means ± SEM (n = 7–9).ures 3E and 3F). In contrast, in wt mice, high-fat diet feeding
completely abolished insulin’s ability to suppress hepatic glu-
cose production (Figure 3F).
Enhanced hepatic insulin sensitivity in high-fat-fed
mtGPAT1−/− mice after short-term insulin exposure was asso-
ciated with a 1.3-fold increased insulin-receptor substrateCELL METABOLISM : JULY 2005ure 4D) and a 1.4-fold increased Akt2 activity (Figure 4E) in
liver. The activation of PKC has recently been implicated in
high-fat-diet-induced hepatic insulin resistance in rats (Samuel
et al., 2004). Hepatic PKC activity, as reflected by the ratio of
PKC in cellular membranes and the cytosolic fraction, was
markedly decreased in the livers of high-fat-fed mtGPAT1−/−57
A R T I C L EFigure 3. Euglycemic-hyperinsulinemic clamp experiments
wt and mtGPAT1−/− mice fed a control diet or a high-fat diet for 3 weeks were
16 hr food-deprived prior to euglycemic-hyperinsulinemic (2.5 mU/kg/min) clamp
experiments. Plasma glucose under hyperinsulinemic conditions was maintained
by an intravenous variable 20% glucose infusion, and rates of (A and B) glucose
infusion, (C and D) peripheral glucose uptake, and (E and F) insulin-mediated
suppression of hepatic glucose production were determined under steady-state
conditions. Results are expressed as means ± SEM (n = 4–5 control diet, n = 7–8
high-fat diet).58Figure 4. Hepatic insulin sensitivity and hepatic insulin signaling
Hepatic glucose production in wt and mtGPAT1−/− mice fed a high-fat diet for 3
weeks was determined under (A) basal and (B) insulin-stimulated conditions in
euglycemic-hyperinsulinemic (2.5 mU/kg/min) clamp experiments. (C) Immu-
noblots determining membrane and cytosolic PKC content were performed with
liver protein extracts from fasting high-fat-diet-fed mice. (D and E) Kinase assays
were performed with liver protein extracts obtained from fasted, high-fat-fed
mice 20 min after an intraperitoneal insulin injection (0.5 mU/kg). Results are
expressed as means ± SEM (n = 6–8).Despite no evidence for a genotypic difference in the expres-
sion of the gluconeogenic enzyme PEPCK under insulin-stim-
ulated conditions (100 ± 11, n = 9 versus 108 ± 11, n = 9%
copies/18S rRNA in wt), insulin increased SREBP-1c gene ex-
pression 1.5-fold in high-fat-diet-fed mtGPAT1−/− relative to wt
mice (100 ± 11, n = 8 versus 169 ± 12, n = 8% copies/18S
rRNA in wt), whereas under fasting conditions, SREBP-1c gene
expression was unaltered (100 ± 14, n = 8 versus 116 ± 11,
n = 8% copies/18S rRNA in wt).
There was no effect of systemic mtGPAT1 deletion on pe-
ripheral glucose utilization (Figure 3D) and insulin-stimulated
2-[14C]DG uptake in gastrocnemii muscles (299 ± 50, n = 6
versus 298 ± 33, n = 8 nmol/g skeletal muscle/min glucose in
wt). White adipose tissue, which also displays high mtGPATactivity, had an w30% increase in insulin-stimulated 2-[14C]DG
uptake in mtGPAT1−/− compared to wt mice (108 ± 14, n = 7
versus 72 ± 5, n = 8 nmol/g adipose tissue/min glucose in wt,
p < 0.03).
Improved hepatic insulin sensitivity in high-fat-diet-fed
mtGPAT1−/− mice is associated with decreased
lysophosphatidic acid, diacylglycerol, and triacylglycerol
content but increased acyl-CoA content
Deletion of mtGPAT1 limited the acylation of glycerol-3-phos-
phate, resulting in a 1.6-fold increase in the intrahepatic acyl-
CoA pool in the high-fat-diet mtGPAT1−/− relative to wt mice
(Table 2; Figure 5A). In addition, insulin stimulation caused a
further 2.7-fold increase in acyl-CoA in high-fat-diet-fed
mtGPAT1−/− compared to wt mice (624.5 ± 52.1, n = 7 versusCELL METABOLISM : JULY 2005
Mitochondrial GPAT and insulin resistanceTable 2. Tissue lipid metabolites from high-fat-diet-fed fasting wt and
mtGPAT1−/− mice
wt mtGPAT1−/−
Total liver lipid metabolites
Acyl-CoA (nmol/g liver) 631.9 ± 33.5 (n = 7) 1038.4 ± 56.0*** (n = 7)
Lysophosphatidic acid (nmol/ 3.9 ± 0.1 (n = 5) 0.6 ± 0.0*** (n = 6)
g liver)
Phosphatidic acid (nmol/g liver) 11.9 ± 0.3 (n = 5) 11.2 ± 0.4 (n = 6)
Diacylglycerol (mol/g liver) 3.27 ± 0.42 (n = 7) 1.43 ± 0.14** (n = 6)
Triacylglycerol (mol/g liver) 53.6 ± 4.3 (n = 15) 35.8 ± 2.0** (n = 15)
Total skeletal muscle metabolites
Acyl-CoA (nmol/g muscle) 30.5 ± 6.5 (n = 7) 31.2 ± 5.7 (n = 5)
Triacylglycerol (mol/g muscle) 12.9 ± 3.6 (n = 7) 12.8 ± 3.2 (n = 7)
Lipid metabolites were extracted from freeze-clamped livers and gastrocnemii
muscles obtained from fasting wt and mtGPAT1−/− mice after 3 weeks of high-
fat-diet feeding. Total acyl-CoA, lysophosphatidic acid, and diacylglycerol con-
centrations are given as the sum of the individual metabolite species (*p < 0.03;
**p < 0.005; ***p < 0.00005).content was markedly reduced in high-fat-diet-fed mtGPAT1 High-fat feeding raised hepatic triacylglycerol concentrations
Figure 5. Hepatic lipid metabolite profiles
(A) acyl-CoA, (B) lysophosphatidic acid, and (C) dia-
cylglycerol species (depicts only a fraction of mea-
sured species) were extracted from livers of fasting
wt and mtGPAT1−/− mice fed a high-fat diet for 3
weeks. Species were measured with an API 3000
tandem mass spectrometer interfaced with a turbo
ionspray source in negative electrospray mode. Re-
sults are expressed as means ± SEM (n = 7–8).234.6 ± 26.6, n = 7 nmol/g liver total post-clamp acyl-CoA in
wt, p < 0.0001).
Under fasting conditions, total hepatic lysophosphatidic acid
−/−CELL METABOLISM : JULY 2005compared to wt mice (Table 2; Figure 5B). Intracellular lyso-
phosphatidic acid abundance has been connected to phos-
phorylation and activation of glycogen synthase kinase 3
(pGSK-3) in the past. In the presence of decreased lysophos-
phatidic acid levels, the hepatic pGSK-3 content tended to be
lower in fasting high-fat-diet-fed mtGPAT1−/− than in wt mice
(2.2 ± 0.5, n = 7 versus 1.6 ± 0.3, n = 7 fold-change in pGSK-3
relative to control diet). Insulin markedly elevated total hepatic
LPA content (13.2 ± 2.5, n = 3 versus 4.1 ± 0.3, n = 6 nmol/g
liver total post-clamp LPA in wt) in mtGPAT1−/− mice, affecting
the majority of measured species to a similar extent (data not
shown). Total hepatic phosphatidic acid content as well as all
individual phosphatidic acid species (data not shown) showed
no genotypic differences in high-fat-diet-fed mice (Table 2).
Total hepatic diacylglycerol content as well as various indivi-
dual diacylglycerol species were markedly reduced in livers of
high-fat-diet-fed mtGPAT1−/− compared to wt mice (Table 2;
Figure 5C). No marked genotypic differences were evident
when the control diet was fed to mtGPAT1−/− and wt mice
(data not shown).
When fed the control diet, mtGPAT1−/− mice displayed a
markedly lower hepatic triacylglycerol content (4.0 ± 0.5, n = 5
versus 8.8 ± 1.7, n = 5 mol/g liver triacylglycerol, p = 0.02).59
A R T I C L E7- and 10-fold in wt and mtGPAT1−/− mice, but the total he-
patic triacylglycerol content in mtGPAT1−/− mice remained sig-
nificantly below that measured in wt mice (Table 2).
The absence of mtGPAT1 in mice did not alter the acyl-CoA
or triacylglycerol concentrations in skeletal muscle with high-
fat-diet feeding (Table 2).
Hepatic pAMPK protein content, pACC protein content,
and malonyl-CoA levels are not altered in livers
of high-fat-diet-fed mtGPAT1−/− mice
A 40% increase in fasting plasma β-hydroxybutyrate concen-
trations (Table 1) in high-fat-diet-fed mtGPAT1−/− mice likely
reflected higher rates of hepatic fatty-acid β-oxidation and thus
we assessed key regulatory mechanisms of fatty-acid β-oxida-
tion in liver. The hepatic protein content of phosphorylated
AMP-activated protein kinase (Supplemental data available
with this article online), phosphorylated acetyl-CoA carboxyl-
ase (Supplemental data), and hepatic malonyl-CoA (2.3 ± 0.8,
n = 4 versus 2.4 ± 0.6, n = 3 nmol/g liver malonyl-CoA in wt)
were comparable in the mtGPAT1−/− and wt genotypes. De-
spite marked increases of n-3 fatty-acid derivatives in livers of
mtGPAT1−/− mice (Figure 5A), neither the expression of PPARα
(100 ± 11, n = 9 versus 88 ± 11, n = 9% copies/18S rRNA
in wt) nor the PPARα-responsive gene peroxisomal acyl-CoA
oxidase 1 (100 ± 11, n = 9 versus 114 ± 11, n = 9% copies/
18S rRNA in wt) differed between genotypes. The hepatic ex-
pression of the VLCAD gene (100 ± 13, n = 6 versus 114 ± 14,
n = 6% copies/18S rRNA in wt) and the LCAD gene (100 ± 11,
n = 9 versus 102 ± 11, n = 9% copies/18S rRNA in wt), both
involved in fatty-acid β-oxidation, were similar in high-fat-fed
mtGPAT1−/− and wt mice.
Discussion
Here we show that systemic mtGPAT1 deletion substantially
limits the incorporation of acyl-CoA species into the sn-glyc-
erol 3-phosphate pathway in liver resulting in markedly lower
hepatic triacylglycerol but higher acyl-CoA abundance and in-
creased plasma β-hydroxybutyrate concentrations, most likely
as a result of increased hepatic ketogenesis. Therefore, the two
alternative GPAT isoforms mtGPAT2 and msGPAT appear to be
incapable of compensating for mtGPAT1 in liver.
Surprisingly, systemic deletion of mtGPAT1 completely pro-
tected mice from developing high-fat-diet-induced hepatic in-
sulin resistance despite a large increase in hepatic acyl-CoA
content. Improved hepatic insulin action in mtGPAT1−/− mice
was also evident in enhanced hepatic insulin signaling, tran-
scriptional induction of the insulin-responsive gene SREBP-1c,
and a pronounced insulin-mediated decline in plasma β-hydroxy-
butyrate levels, the latter likely the result of an enhanced in-
sulin-mediated suppression of hepatic ketogenesis. The fact
that increased tissue-specific insulin sensitivity in high-fat-fed
mtGPAT1−/− mice was exclusively evident in liver and white ad-
ipose tissue but not skeletal muscle is consistent with the en-
zyme’s tissue-specific activity pattern. In rat it has been re-
ported that in the majority of tissues, including skeletal muscle,
mtGPAT comprises only 10% of total GPAT enzyme activity
whereas in liver and white adipose tissue mtGPAT can com-
prise up to 50% of total GPAT enzyme activity (Coleman et al.,
2000; Lewin et al., 2001). The improved hepatic insulin sensitiv-
ity in mtGPAT1−/− mice was not mediated by changes in major60circulating adipocyte cytokines as plasma leptin, adiponectin,
and resistin concentrations were unchanged.
Previous studies have linked the accumulation of various
lipid metabolites, such as acyl-CoA species, lysophosphatidic
acid, diacylglycerol, or triacylglycerol in liver and skeletal mus-
cle with the pathogenesis of insulin resistance (Chen et al.,
1992; Griffin et al., 1999; Hegarty et al., 2003; Jucker et al.,
1999; Kraegen et al., 2001; Petersen et al., 2004; Samuel et
al., 2004; Shulman, 2000; Yu et al., 2002). As demonstrated in
this study, systemic deletion of mtGPAT1 affects the abun-
dance of lipid metabolites primarily in the liver, and the ab-
sence of major physiologic and metabolic changes makes this
an ideal model to study the role of an array of lipid candidates
in the genesis of hepatic insulin resistance.
An important finding in the current study is that despite an
almost 2-fold increase in the abundance of long-chain and very
long-chain acyl-CoA species in the liver, high-fat-diet-fed
mtGPAT1−/− mice were protected from fat-induced hepatic in-
sulin resistance, providing strong evidence against a role of
acyl-CoA species in mediating this pathologic process.
A role of lysophosphatidic acid as a mediator of insulin resis-
tance has also been suggested in the past. Systemic deletion
of mtGPAT1 resulted in a very pronounced reduction of hepatic
lysophosphatidic acid concentrations under fasting conditions and
was accompanied by a tendency for a lower hepatic pGSK-3
protein content in mtGPAT1−/− mice. Lysophosphatidic acid
has been shown to be capable of inducing the phosphory-
lation and activation of the serine/threonine kinase GSK-3
primarily via a protein kinase C-dependent pathway and
thereby could interfere with insulin signaling (Fang et al., 2002).
Surprisingly, insulin stimulation markedly raised hepatic lyso-
phosphatidic acid content in mtGPAT1−/− compared to wt
mice. Since mtGPAT1−/− mice were protected from fat-induced
hepatic insulin resistance, these data argue against a major
role for lysophosphatidic acid in mediating fat-induced hepatic
insulin resistance. The fact that C16:0 lysophosphatidic acid
dominated the spectrum suggests that the majority of hepatic
lysophosphatidic acid was not directly synthesized from di-
etary C18:2n-6, the most abundant fatty-acid species in saf-
flower oil. It rather appears that lysophosphatidic acid was
mainly derived from de novo lipogenesis and/or from induction
of phospholipase A by insulin (Shashkin et al., 2001).
In contrast to the other lipid metabolites, hepatic diacylglyc-
erol content was the most consistent predictor of hepatic insu-
lin sensitivity in high-fat-diet-fed mtGPAT1−/− mice. Diacylglyc-
erol has been shown to activate an array of PKC isoenzymes
that are capable of inhibiting insulin receptor tyrosine kinase
activity by initiation of serine/threonine phosphorylation of the
insulin receptor or insulin receptor substrate (Considine et al.,
1995; Ikeda et al., 2001; Nishizuka, 2003; Samuel et al., 2004;
Takai et al., 1979; Yu et al., 2002). A possible role for decreased
diacylglycerol levels in preserving hepatic insulin sensitivity is
supported by the observation of decreased hepatic PKC acti-
vation in high-fat-fed mtGPAT1−/− mice (Figure 4C).
The role of triacylglycerol in the genesis of insulin resistance
is unclear. While intramyocellular lipid content is an excellent
marker for insulin resistance in skeletal muscle of sedentary
individuals (Krssak et al., 1999; Perseghin et al., 1999; Petersen
et al., 2004), recent animal studies have been able to dissociate
intramuscular triacylglycerol content from fat-induced insulin
resistance in skeletal muscle (Yu et al., 2002). Most studies toCELL METABOLISM : JULY 2005
Mitochondrial GPAT and insulin resistancedate both in humans and animal models, including the present
study, have found a strong relationship between hepatic tri-
acylglycerol content and hepatic insulin sensitivity (Bajaj et al.,
2004; Chou et al., 2002; Jucker et al., 1999; Petersen et al.,
2005; Samuel et al., 2004; Voshol et al., 2003). Whether hepatic
triacylglycerol is the actual trigger or merely a marker for fat-
induced hepatic insulin resistance remains to be determined.
A number of mouse models lacking enzymes that are involved
in triacylglycerol synthesis and cause alterations in lipid ho-
meostasis have been generated in the past few years. Mice
deficient in acyl-CoA:diacylglycerol transferase 1 (DGAT1), cat-
alyzing the final step in the glycerol 3-phosphate pathway,
share several phenotypic similarities with mtGPAT1−/− mice
(Chen et al., 2002; Smith et al., 2000). DGAT1−/− mice are
lean, have smaller fat pads, and lack alterations in plasma glu-
cose, insulin, and fatty-acid concentrations. But in contrast to
mtGPAT1−/− mice, DGAT1−/− mice are hypoleptinemic, hyper-
sensitive to leptin and insulin, normotriglyceridemic, display a
markedly lower triacylglycerol content in skeletal muscle but
not liver, and are resistant to diet-induced obesity through a
mechanism involving increased energy expenditure and activity
(Chen et al., 2002; Smith et al., 2000). DGAT2, the second char-
acterized DGAT isoenzyme, is essential for triacylglycerol syn-
thesis. DGAT2−/− mice die early in the postnatal period proba-
bly due to an impaired permeability barrier function in the skin
and from a lack of key substrates for energy metabolism and
triacylglycerol synthesis during development (Stone et al.,
2004).
It has been demonstrated previously that mtGPAT1 overex-
pression in hepatocytes reduces the oxidation of radiolabeled
palmitic and oleic acid (Lewin et al., 2005, Lindén et al., 2004).
As rates of fatty-acid oxidation and ketogenesis usually corre-
late, increased fasting plasma β-hydroxybutyrate concen-
trations in high-fat-diet-fed mtGPAT1−/− mice likely reflect an
increase in fatty-acid β-oxidation. Stearoyl-CoA desaturase
(SCD) catalyzes the rate-limiting step in the biosynthesis of
monounsaturated fatty acids. SCD−/− mice display increased
fatty-acid β-oxidation rates likely involving AMPK-induced in-
activation of acetyl-CoA carboxylase and subsequent intracel-
lular decreases in the carnitine palmitoyltransferase 1 (CPT-1)
inhibitor malonyl-CoA (Dobrzyn et al., 2004). In contrast to
SCD−/− mice, the present findings suggest that different regula-
tory mechanisms modulate hepatic fatty-acid β-oxidation in
mtGPAT1−/− mice since the hepatic content of pAMPK protein,
pACC protein, and malonyl-CoA were similar in mtGPAT1−/−
and wt mice.
Another regulator of hepatic fatty-acid oxidation is the
nuclear transcription peroxisome proliferator-activated recep-
tor α (PPARα) that once activated induces gene transcription
of an array of enzymes involved in mitochondrial and peroxi-
somal β-oxidation and microsomal ω-oxidation (Bardot et al.,
1993; Bars et al., 1993; Besnard et al., 1993; Hijikata et al.,
1990; Osumi et al., 1991). The n-3 fatty acids C20:5n-3 or
C22:6n-3 have been shown to serve as PPARα ligands and
promote hepatic peroxisome proliferation in vivo (Forman et al.,
1997; Hashimoto et al., 1999; Neschen et al., 2002). However,
despite an increase in hepatic n-3 fatty-acid-derived CoA spe-
cies in mtGPAT1−/− mice neither the expression of PPARα or
of the PPARα responsive gene peroxisomal acyl-CoA oxidase
1 differed between genotypes.
In conclusion, mtGPAT1−/− mice were protected from high-CELL METABOLISM : JULY 2005fat-diet-induced hepatosteatosis and hepatic insulin resis-
tance. Consistent with mtGPAT1’s tissue distribution, this pro-
tection from fat-induced insulin resistance was restricted to
liver and white adipose tissue but not skeletal muscle. In
mtGPAT1−/− mice, preservation of hepatic insulin sensitivity
in vivo correlated with enhanced insulin signaling on the cellu-
lar level but was not related to increased intrahepatic acyl-CoA
concentrations, implying that acyl-CoA’s do not mediate fat-
induced hepatic insulin resistance. In contrast, protection of
fat-induced hepatic insulin resistance was correlated with re-
duced fasting concentrations of diacylglycerol, further implicat-
ing this metabolite as a potentially important mediator of fat-
induced hepatic insulin resistance. These data also suggest
that mtGPAT1 might be a potent therapeutic target to treat he-
patic steatosis and hepatic insulin resistance.
Experimental procedures
Animals and dietary treatment
Male, age-matched mice deficient in mtGPAT (mtGPAT1−/−, C57BL/6J ge-
netic background, F6 generation; Hammond et al., 2002) and wild-type (wt)
mice were singly housed, and in order to minimize stress to the animals,
experiments were carried out in several separate but identically treated
groups of mice. While on a control diet (Teklad LM-485, 7912, 5% wt/wt
soybean oil, Harlan, Madison, Wisconsin), a first set of intraperitoneal glu-
cose tolerance tests (1 g glucose/kg) was performed. At an age of 14–21
weeks mice, were started on a high-fat safflower oil based diet (27% wt/wt
safflower oil, 59% fat-derived calories, 5.18 kcal/g) and fed for 3 weeks.
The safflower oil diet (#112245, Dyets, Bethlehem, Pennsylvania) was sup-
plemented with minerals and vitamins (#210025, #310025). Food was ex-
changed every third day and individual food consumption rates, body
weight gain, and body composition using in vivo NMR-spectroscopy (Min-
ispec MQ10 analyzer, Bruker Optics Inc, Billerica, Massachusetts) were
measured at baseline and weekly throughout dietary intervention. After 1
week of high-fat feeding, a second set of intraperitoneal glucose tolerance
tests (1 g glucose/kg) was carried out. From further mouse batches, plasma
and tissue samples under basal or after 20 min insulin-stimulated condi-
tions (intraperitoneal 0.5 mU/kg) were harvested under isoflurane anesthe-
sia. Fat absorption from a semi-synthetic low-fat or high-fat diet (7% or
27% wt/wt safflower oil) supplemented with 5% sucrose polybehenate, a
marker for the intestinal transit of dietary fat, was assessed according to
techniques described earlier (Jandacek et al., 2004). Fat absorption was
calculated from the ratios of behenic acid to linolenic acid in diet and feces
collected on day two analyzed by gas chromatography of fatty-acid methyl
esters. All experiments were carried out in 16 hr food-deprived mice, except
intraperitoneal glucose tolerance tests after 1 week of high-fat feeding,
where food was removed 6 hr prior to the experiment. All procedures were
approved by the Yale University Animal Care and Use Committee.
Euglycemic-hyperinsulinemic glucose clamp experiments
One week prior to experiments, an intravenous silicone catheter was in-
serted into the right jugular vein under ketamine/xylazine anesthesia (intra-
peritoneal 80/10 mg/kg body weight). On the experimental day, the subcu-
taneously located sealed catheter-tip was accessible via a small
interscapular skin incision. Conscious mice were placed in restraining
tubes, their tails secured with tape. In vivo experiments lasted for 240 min
and consisted of a 120 min basal period directly followed by a 120 min
euglycemic-hyperinsulinemic clamp as previously described (Ren et al.,
1995). During the basal period, a prime-continuous [3-3H]glucose infusion
(10 Ci bolus, 0.1 Ci/min) was started and continued to determine rates
of whole-body glucose turnover. After the 120 min basal infusion period,
a primed-continuous insulin infusion (2.5 mU/kg*min−1; Humulin, Eli Lilly,
Indianapolis, Indiana) was started at time 0 min, raising insulin levels within
a physiologic range (control diet: 75 ± 2, n = 4 versus 74 ± 5, n = 5 U/ml
insulin in wt, p = 0.9; high-fat diet: 67 ± 3, n = 7 versus 66 ± 2, n = 8 U/
ml insulin in wt, p = 0.8). “Steady-state” conditions for plasma glucose
concentration (control diet: 118 ± 4, n = 4 versus 114 ± 9, n = 5 mg/dl
glucose in wt, p = 0.7; high-fat diet: 105 ± 5, n = 7 versus 117 ± 4, n = 861
A R T I C L Emg/dl glucose in wt, p = 0.08) and specific activity were achieved within
70 min, and a single 2-deoxy-D-[1-14C]glucose (2-[14C]DG) injection was
administered at time 75 min. To determine plasma [3-3H]glucose, 3H2O, and
2-[14C]DG concentrations, blood samples were collected at time 80, 85, 90,
100, 110, and 120 min of the clamp and for measurement of basal
[3-3H]glucose concentrations in the final 10 min of the basal period. A
plasma sample for determination of basal insulin levels was obtained during
the final 10 min of the basal period and for steady-state insulin levels at
minute 120 of the clamp. All infusions were performed with microdialysis
pumps (CMA/Microdialysis, North Chelmsford, Massachusetts) and radio-
isotopes purchased from Perkin Elmer Life Sciences (Boston, Massachu-
setts) and American Radiolabeled Chemicals (St. Louis, Missouri). At the
end of the experiment, animals were anesthetized with ketamine/xylazine
(intravenous 80/10 mg/kg) and liver, epididymal white adipose tissue, and
M. gastrocnemius including M. soleus were immediately freeze-clamped
and stored at −80°C until further analysis.
Calculations
The rate of whole-body glucose turnover was calculated as the ratio of
[3-3H]glucose infusion rate (dpm/min) and plasma [3-3H]glucose-specific
activity (dpm/min*mol) during steady state. Hepatic [3-3H]glucose produc-
tion (HGP) was determined by subtracting the steady-state glucose infusion
rate (GINF) from the rate of glucose whole-body turnover. 2-[14C]DG uptake
in gastrocnemius muscle and epididymal white adipose tissue were calcu-
lated from plasma 2-[14C]DG AUC at minute 80, 85, 90, 100, 110, to 120
and tissue 2-[14C]DG-6-phosphate content as described previously (Oh-
shima et al., 1984).
Assays from plasma
Glucose concentration was determined with a Glucose Analyzer (Beckman,
Fullerton, California), triacylglycerol, nonesterified fatty-acid, β-hydroxybu-
tyrate, cholesterol, and HDL cholesterol levels with a Cobas Mira Analyzer
(Roche Diagnostics). Plasma insulin, glucagon, leptin, adiponectin (Linco
Research, St. Charles, Missouri), and corticosterone (ICN, Costa Mesa,
California) were measured via radioimmunoassay. Plasma [3-3H]glucose
and 2-[14C]DG was determined from deproteinized plasma samples (So-
mogyi filtrates) after 3H2O was completely evaporated from the supernatant
using a Liquid Scintillation Counter (Ultima Gold; Packard Instrument Co,
Meriden, Connecticut).
Tissue 2-[14C]DG-6P enrichment
2-[14C]DG injected during steady-state conditions of euglycemic-hyperin-
sulinemic clamp experiments resulted in intracellular accumulation of
2-[14C]DG-6P in tissue. 2-[14C]DG-6P in gastrocnemius muscle and epidid-
ymal white adipose tissue homogenates was separated from 2-[14C]DG
using ion-exchange columns (Poly-Prep #731-6211; Bio-Rad, Hercules,
California) according to a technique previously described (Griffin et al.,
1999).
Tissue lipid metabolites
The extraction procedure for acyl-CoA species was adapted from methods
described previously (Deutsch et al., 1994; Neschen et al., 2002). Approxi-
mately 100 mg of liver or skeletal muscle (M. quadriceps) tissue were ho-
mogenized with C17:0 acyl-CoA-ester internal standard. After purification
using Oligonucleotide Purification Cartridges (Applied Biosystems, Foster
City, California) and a drying step, medium, long-chain, and very long-chain
acyl-CoA fractions were dissolved in methanol/H2O (1:1, v/v).
For lysophosphatidic and phosphatidic acid measurements, approxi-
mately 100 mg of liver tissue was homogenized in chloroform/methanol
(1:1 vol/vol) with 1 nmol/l C17-lysophosphatidic acid internal standard. After
phase separation with dH2O, samples were homogenized, centrifuged, and
the methanol/water phase collected. The supernatant was applied to condi-
tioned Waters Oasis MAX extraction cartridges (Waters Corporation, Mil-
ford, Massachusetts). After a washing step, lysophosphatidic and phospha-
tidic acid species were eluted using methanol.
The extraction procedure for diacylglycerol was adapted from methods
described previously (Pacheco et al., 1998). Approximately 100 mg of liver
tissue was homogenized in ice-cold chloroform/methanol (2:1 vol/vol) con-
taining 0.01% butylated hydroxytoluene and the internal standards 1,3-
dipenta decanoin and 1,2,3-triheptadecanoate. Organic and aqueous phase62were separated adding chloroform and H2O. After centrifugation, the or-
ganic layer was collected, dried under nitrogen flow, and reconstituted with
hexane/methylene chloride/ether (95/4.5/0.5 vol/vol/vol). Diacylglycerol was
separated from triacylglycerol using preconditioned columns (Waters Sep-
Pak Cartridge WAT020845, Milford, Massachusetts) and eluted with hex-
ane/ethyl acetate (85/15 vol/vol) under a low negative pressure.
Lipid metabolite extracts were subjected to LC/MS/MS analysis. A turbo
ionspray source was interfaced with an API 3000 tandem mass spectrome-
ter (Applied Biosystems, Foster City, California) in conjunction with two Per-
kin Elmer 200 Series micro pumps and a 200 Series autosampler (Perkin
Elmer, Norwalk, Connecticut). Total acyl-CoA, lysophosphatidic acid, phos-
phatidic acid, and diacylglycerol content were expressed as the sum of
individual species.
Tissue triacylglycerol content
The extraction procedure for tissue triacylglycerol was adapted from meth-
ods described previously (Frayn and Maycock, 1980; Neschen et al., 2002).
Triacylglycerol content of each sample was measured in duplicate after
evaporation of the organic solvent using an enzymatic method (Sigma Diag-
nostics, St. Louis, Missouri).
Tissue malonyl-CoA content
Approximately 100 mg of liver tissue were homogenized in ice-cold 10%
trichloroacetic acid with the addition of 13C3-malonyl-CoA internal standard.
After centrifugation, the supernatant was applied to a preconditioned car-
tridge (C18 Waters Sep-Pak Cartridge WAT036905, Milford, Massachusetts)
and following washing steps eluted with 65% ethanol containing 0.1 M
NH4-acetate and 50% methanol. Samples were lyophilized and redissolved
in water. Malonyl-CoA and acetyl-CoA were separated by HPLC with
isocratic 15% methanol and 10 mM ammonium acetate and measured
using LC/MS/MS analysis.
Western blot analysis
Proteins extracted from freeze-clamped basal liver tissue were resolved by
electrophoresis and electrotransferred onto PVDF membranes (Amersham
Pharmacia Biotech Inc.). Membranes were immunoblotted with antibodies
recognizing phosphorylation of AMP-activated protein kinase α-1/α-2 at
Thr172, phosphorylation of acetyl-CoA carboxylase α/β at Ser97, or phos-
phorylation of glycogen synthase kinase-3 α/β at Ser21 and Ser9 (Cell Sig-
naling Technology, Beverly, Massachusetts).
PKC membrane translocation assays were performed according to
methods previously described (Qu et al., 1999; Donnelly et al., 1994). Briefly,
50 g of crude membrane and cytosol protein extracts were resolved by
SDS-PAGE using an 8% gel and electrotransferred onto PVDF. Membranes
were immunoblotted with a rabbit anti-peptide antibody against PKC
(Santa Cruz Biotechnology, Santa Cruz, California) diluted 1:100 in rinsing
solution. PKC translocation was expressed as the ratio of arbitrary units of
membrane bands over cytosol bands.
Protein bands were quantitated using a Bio-Rad Chemidoc SRX and
Quantity One Software (Biorad, Hercules, California).
Liver IRS2-associated PI3K and Akt2 activity
IRS2-associated PI3K and Akt2 activity were assessed in 4 mg protein ex-
tracts from livers harvested after short-term insulin stimulation. Assays were
performed according to methods previously described (Alessi et al., 1996;
Folli et al., 1992). Primary antibodies used for these experiments were rabbit
polyclonal IgG. All materials were obtained from Upstate (Charlottesville,
Virginia).
Quantitative RT-PCR-based gene expression analysis
RNA was isolated from post-clamp livers using a commercially available kit
(Qiagen RNeasy Kit, Qiagen Inc, Valencia, California) in combination with
DNase digest treatment. After 1.5 g of total RNA were reverse transcribed
(Stratagene, La Jolla, California) with an oligo-prime, PCR was performed
with a DNA Engine Opticon 2 System (MJ Research, Boston, Massachu-
setts) using SYBR green QPCR dye kit (Stratagene). The following primers
were used: phosphoenolpyruvate carboxykinase (PEPCK): 5# ACC TCC
TGG AAG AAC AAG GA 3# (F) and 5# CTC ATG GCT GCT CCT ACA AA 3#
(R); sterol regulatory-element binding protein 1c (SREBP1c): 5# CAT GGA
TTG CAC ATT TGA AGA 3# (F) and 5# CTG TGT CCC CTG TCT CAC C 3#CELL METABOLISM : JULY 2005
Mitochondrial GPAT and insulin resistance(R); peroxisome proliferator-activated receptor α: 5# TAT TCG GCT GAA
GCT GGT GTA CC 3# (F) and 5# CTG GCA TTT GTT CCG GTT CT 3# (R);
peroxisomal acyl-CoA oxidase 1: 5# AGC TCC GAT CAG CCA GAC AT 3#
(F) and 5# TTC TTG AAA CAG AGC CCA GAA TG 3# (R); long-chain acyl-
CoA dehydrogenase: 5# CAC TCA GAT ATT GTC ATG CCC T 3# (F) and
5# TCC ATT GAG AAT CCA ATC ACT C 3# (R); very long-chain acyl-CoA
dehydrogenase: 5# CCT GAA GAA TCC TTT TGG AAA C 3# (F) and 5# CTT
TCT TGT GTT TCA CCA GCT T 3# (R); 18S rRNA: 5# TTC CGA TAA CGA
ACG AGA CTC T 3# (F) and 5# TGG CTG AAC GCC ACT TGT C 3# (R).
Product specificity was verified by running products on an agarose gel.
Messenger RNA levels (CT values), normalized to 18S rRNA, were ex-
pressed using the comparative method. 18S rRNA levels showed no statis-
tical difference between genotypes.
Statistical analysis
All data are expressed as mean ± SEM. Statistical analyses were made
using a two-tailed Student’s t test, and for all hypotheses, the significance
level was 0.05.
Supplemental data
Supplemental data include one figure and are available with this article on-
line at http://www.cellmetabolism.org/cgi/content/full/2/1/55/DC1/.
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